Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30996521 | 0.85 | — | — | |
| SCHEMBL21888983 | 0.74 | APAF1 (0.34) | AOC3 | |
| SCHEMBL23264164 | 0.73 | AOC3 (0.31) | AOC3 | |
| SCHEMBL22121985 | 0.70 | AOC3 (0.53) | AOC3 | |
| SCHEMBL23264478 | 0.70 | AOC3 (0.33) | AOC3 | |
| SCHEMBL25463501 | 0.68 | AOC3 (0.32) | AOC3 | |
| SCHEMBL23277314 | 0.68 | AOC3 (0.40) | AOC3 | |
| SCHEMBL23039982 | 0.68 | CYP19A1 (0.31) | — | |
| SCHEMBL23040121 | 0.68 | MAPK1 (0.42) | AOC3 | |
| SCHEMBL6915240 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620955-A1 | MC4R ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2025-09-24 | — | — | EP | disclosed |
| EP-4444708-B1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-120202199-A | MC4R antagonist compound, pharmaceutical composition and application thereof in medicine | 长春金赛药业有限责任公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-116113635-B | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | PFIZER INC. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4161927-B9 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4161927-B1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118369317-A | Melanocortin 4 receptor antagonists and uses thereof | 辉瑞大药厂 | 2024-07-19 | — | — | CN | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| CN-116113635-A | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4161927-A1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2023275715-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2021250541-A1 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | CSPP1, PRNP, RPLP2 | AOC3 829/4885 |
| US-20230019853-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC5R | AOC3 1745/4885 |
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | MC4R, MC2R, NPY4R | AOC3 1363/4885 |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC2R | AOC3 2290/4885 |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | MC4R, MC3R, MC5R | AOC3 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.